-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
IDEAYA Biosciences (NASDAQ:IDYA) Given New $32.00 Price Target at Guggenheim
IDEAYA Biosciences (NASDAQ:IDYA) Given New $32.00 Price Target at Guggenheim
IDEAYA Biosciences (NASDAQ:IDYA – Get Rating) had its price objective boosted by Guggenheim from $20.00 to $32.00 in a research note released on Tuesday, The Fly reports. The brokerage currently has a buy rating on the stock.
Several other equities research analysts have also issued reports on IDYA. Stifel Nicolaus lowered IDEAYA Biosciences from a buy rating to a hold rating and decreased their target price for the company from $16.00 to $13.00 in a research report on Monday, August 15th. Roth Capital raised their target price on IDEAYA Biosciences from $42.00 to $46.00 in a research report on Tuesday, May 17th. Oppenheimer raised their target price on IDEAYA Biosciences to $22.00 in a research report on Tuesday, September 6th. Finally, Robert W. Baird decreased their target price on IDEAYA Biosciences from $26.00 to $18.00 and set an outperform rating for the company in a research report on Tuesday, August 16th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat, IDEAYA Biosciences has a consensus rating of Moderate Buy and an average target price of $27.50.
Get IDEAYA Biosciences alerts:IDEAYA Biosciences Trading Down 5.1 %
NASDAQ IDYA opened at $11.16 on Tuesday. The firm has a market capitalization of $438.65 million, a P/E ratio of -6.53 and a beta of 1.51. The business has a fifty day simple moving average of $12.84 and a 200 day simple moving average of $12.01. IDEAYA Biosciences has a 12 month low of $8.14 and a 12 month high of $27.71.
IDEAYA Biosciences (NASDAQ:IDYA – Get Rating) last released its quarterly earnings results on Monday, August 15th. The company reported ($0.57) EPS for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.06). IDEAYA Biosciences had a negative net margin of 225.95% and a negative return on equity of 22.38%. As a group, sell-side analysts predict that IDEAYA Biosciences will post -2.27 EPS for the current fiscal year.Institutional Inflows and Outflows
Several large investors have recently added to or reduced their stakes in IDYA. Nisa Investment Advisors LLC bought a new position in IDEAYA Biosciences in the 2nd quarter worth about $25,000. Point72 Hong Kong Ltd boosted its stake in IDEAYA Biosciences by 363.7% in the 1st quarter. Point72 Hong Kong Ltd now owns 3,376 shares of the company's stock worth $38,000 after purchasing an additional 2,648 shares during the period. Quantbot Technologies LP boosted its stake in IDEAYA Biosciences by 90.5% in the 1st quarter. Quantbot Technologies LP now owns 4,000 shares of the company's stock worth $44,000 after purchasing an additional 1,900 shares during the period. Amalgamated Bank bought a new position in IDEAYA Biosciences in the 1st quarter worth about $48,000. Finally, Mitsubishi UFJ Kokusai Asset Management Co. Ltd. boosted its stake in IDEAYA Biosciences by 12.7% in the 1st quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 10,416 shares of the company's stock worth $117,000 after purchasing an additional 1,171 shares during the period. Institutional investors own 93.25% of the company's stock.
IDEAYA Biosciences Company Profile
(Get Rating)
IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase I clinical trial for patients with solid tumors having methylthioadenosine phosphorylase deletions; and IDE196, a protein kinase C inhibitor that is in Phase I/II clinical trial for genetically defined cancers having GNAQ or GNA11 gene mutations.
See Also
- Get a free copy of the StockNews.com research report on IDEAYA Biosciences (IDYA)
- 3 Banks Worth Considering For Q4
- Stock Market: 3 Islands Of Strength In A Sea Of Red
- No One Told These 3 Stocks It's a Down Week
- MarketBeat: Week in Review 9/12 – 9/16
- Is There a Cure for What is Ailing Teladoc Stock?
Receive News & Ratings for IDEAYA Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEAYA Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
IDEAYA Biosciences (NASDAQ:IDYA – Get Rating) had its price objective boosted by Guggenheim from $20.00 to $32.00 in a research note released on Tuesday, The Fly reports. The brokerage currently has a buy rating on the stock.
據The Fly報道,在週二發佈的一份研究報告中,古根海姆將IDEAYA生物科學公司(納斯達克:IDYA-GET評級)的目標價從20.00美元上調至32.00美元。該經紀公司目前對該股的評級為買入。
Several other equities research analysts have also issued reports on IDYA. Stifel Nicolaus lowered IDEAYA Biosciences from a buy rating to a hold rating and decreased their target price for the company from $16.00 to $13.00 in a research report on Monday, August 15th. Roth Capital raised their target price on IDEAYA Biosciences from $42.00 to $46.00 in a research report on Tuesday, May 17th. Oppenheimer raised their target price on IDEAYA Biosciences to $22.00 in a research report on Tuesday, September 6th. Finally, Robert W. Baird decreased their target price on IDEAYA Biosciences from $26.00 to $18.00 and set an outperform rating for the company in a research report on Tuesday, August 16th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat, IDEAYA Biosciences has a consensus rating of Moderate Buy and an average target price of $27.50.
其他幾位股票研究分析師也發佈了關於IDYA的報告。Stifel Nicolaus在8月15日週一的一份研究報告中將IDEAYA Biosciences的評級從買入下調至持有,並將該公司的目標價從16.00美元下調至13.00美元。Roth Capital在5月17日週二的一份研究報告中將IDEAYA Biosciences的目標價從42.00美元上調至46.00美元。奧本海默在9月6日(星期二)的一份研究報告中將他們對IDEAYA生物科學公司的目標價上調至22.00美元。最後,羅伯特·W·貝爾德在8月16日星期二的一份研究報告中將他們對IDEAYA生物科學公司的目標價從26.00美元下調至18.00美元,併為該公司設定了表現優於大盤的評級。一名投資分析師對該股的評級為持有,五名分析師對該公司的評級為買入。根據MarketBeat的數據,IDEAYA Biosciences的共識評級為中等買入,平均目標價為27.50美元。
IDEAYA Biosciences Trading Down 5.1 %
IDEAYA生物科學公司股價下跌5.1%
NASDAQ IDYA opened at $11.16 on Tuesday. The firm has a market capitalization of $438.65 million, a P/E ratio of -6.53 and a beta of 1.51. The business has a fifty day simple moving average of $12.84 and a 200 day simple moving average of $12.01. IDEAYA Biosciences has a 12 month low of $8.14 and a 12 month high of $27.71.
納斯達克IDYA週二開盤報11.16美元。該公司的市值為4.3865億美元,市盈率為-6.53,貝塔係數為1.51。該業務的50日簡單移動均線為12.84美元,200日簡單移動均線為12.01美元。IDEAYA Biosciences的12個月低點為8.14美元,12個月高位為27.71美元。
Institutional Inflows and Outflows
機構資金流入和流出
Several large investors have recently added to or reduced their stakes in IDYA. Nisa Investment Advisors LLC bought a new position in IDEAYA Biosciences in the 2nd quarter worth about $25,000. Point72 Hong Kong Ltd boosted its stake in IDEAYA Biosciences by 363.7% in the 1st quarter. Point72 Hong Kong Ltd now owns 3,376 shares of the company's stock worth $38,000 after purchasing an additional 2,648 shares during the period. Quantbot Technologies LP boosted its stake in IDEAYA Biosciences by 90.5% in the 1st quarter. Quantbot Technologies LP now owns 4,000 shares of the company's stock worth $44,000 after purchasing an additional 1,900 shares during the period. Amalgamated Bank bought a new position in IDEAYA Biosciences in the 1st quarter worth about $48,000. Finally, Mitsubishi UFJ Kokusai Asset Management Co. Ltd. boosted its stake in IDEAYA Biosciences by 12.7% in the 1st quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 10,416 shares of the company's stock worth $117,000 after purchasing an additional 1,171 shares during the period. Institutional investors own 93.25% of the company's stock.
幾家大型投資者最近增持或減持了IDYA的股份。NISA Investment Advisors LLC在第二季度購買了IDEAYA Biosciences的新頭寸,價值約25,000美元。Point72 Hong Kong Ltd在第一季度增持了IDEAYA Biosciences的股份363.7%。Point72 Hong Kong Ltd在此期間額外購買了2,648股,目前持有該公司3,376股股票,價值38,000美元。Quantbot Technologies LP在第一季度增持了IDEAYA Biosciences 90.5%的股份。在此期間,Quantbot Technologies LP又購買了1900股,現在擁有4000股該公司股票,價值4.4萬美元。合併銀行在第一季度購買了IDEAYA生物科學公司的一個新頭寸,價值約48,000美元。最後,三菱UFJ國賽資產管理有限公司在第一季度將其在IDEAYA Biosciences的持股增加了12.7%。三菱UFJ國賽資產管理有限公司在此期間增購了1,171股後,現在持有10,416股該公司股票,價值11.7萬美元。機構投資者持有該公司93.25%的股票。
IDEAYA Biosciences Company Profile
IDEAYA生物科學公司簡介
(Get Rating)
(獲取評級)
IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase I clinical trial for patients with solid tumors having methylthioadenosine phosphorylase deletions; and IDE196, a protein kinase C inhibitor that is in Phase I/II clinical trial for genetically defined cancers having GNAQ or GNA11 gene mutations.
IDEAYA生物科學公司是一家專注於合成致命性的精確醫學腫瘤學公司,專注於為使用分子診斷技術選擇的患者羣體發現和開發靶向療法。該公司的主要候選產品包括甲硫氨酸腺苷轉移酶2a抑制劑IDE397和蛋白激酶C抑制劑IDE196。IDE397是一種蛋氨酸腺苷轉移酶2a抑制劑,正處於甲硫腺苷磷酸化酶缺失的實體腫瘤患者的第一階段臨牀試驗中;IDE196是一種蛋白激酶C抑制劑,正處於針對具有GNAQ或GNA11基因突變的基因定義癌症的第一/第二階段臨牀試驗。
See Also
另請參閲
- Get a free copy of the StockNews.com research report on IDEAYA Biosciences (IDYA)
- 3 Banks Worth Considering For Q4
- Stock Market: 3 Islands Of Strength In A Sea Of Red
- No One Told These 3 Stocks It's a Down Week
- MarketBeat: Week in Review 9/12 – 9/16
- Is There a Cure for What is Ailing Teladoc Stock?
- 免費獲取StockNews.com關於IDEAYA生物科學的研究報告(IDYA)
- 第四季度值得考慮的3家銀行
- 股市:紅海中的三座強國
- 沒有人告訴這三隻股票這是下跌的一週
- MarketBeat:回顧一週9/12-9/16
- 有什麼辦法可以治癒Teladoc股票的問題嗎?
Receive News & Ratings for IDEAYA Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEAYA Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
獲得IDEAYA生物科學日報的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對IDEAYA生物科學和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧